Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case

Denosumab is a highly effective treatment for postmenopausal osteoporosis, significantly improving BMD and reducing risk of fracture. However, denosumab's effect is transient with the risk of a rebound increase in bone turnover following withdrawal of this potent RANKL inhibitor. This poses cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidoff, Dahlia F, Girgis, Christian M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574702/
https://www.ncbi.nlm.nih.gov/pubmed/33103026
http://dx.doi.org/10.1002/jbm4.10396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574702/
https://www.ncbi.nlm.nih.gov/pubmed/33103026
http://dx.doi.org/10.1002/jbm4.10396

Ejemplares similares